Physician profile
Winola S Sprague
NPI 1427276674
$5,576.48
in general payments reported to CMS, 2019-2025
20 companies · $771 in 2025
The $771 reported for 2025 was more than what 84% of Psychiatric/Mental Health, Child & Family providers received nationally (typical 2025 total: $178).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,179 · 2022: $995 · 2023: $1,289 · 2024: $1,343 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,403.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,403.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,398.72 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $765.37 | 2021-2025 | Caplyta |
| Corium, LLC | $668.33 | 2021-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $364.72 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $297.60 | 2022-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $240.63 | 2022-2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $194.35 | 2025 | Jornay Pm |
| Tris Pharma INC | $178.21 | 2021-2025 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $110.78 | 2024 | Cobenfy |
| Janssen Pharmaceuticals, INC | $107.18 | 2023-2024 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $76.57 | 2021-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $34.10 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $32.33 | 2023-2024 | Rexulti |
| Alkermes, INC. | $20.50 | 2023 | Aristada, Lybalvi |
| Vertical Pharmaceuticals, LLC | $16.90 | 2024 | Relexxii |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $16.62 | 2024 | |
| Neos Therapeutics, Lp | $16.29 | 2022 | |
| Noven Therapeutics, LLC | $16.08 | 2025 | Xelstrym |
| Adlon Therapeutics L.P. | $11.20 | 2021 | |
| Neuronetics, INC. | $10.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Winola Sprague listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.